Early Everolimus‐Facilitated Reduced Tacrolimus in Liver Transplantation: Results From the Randomized HEPHAISTOS Trial
Björn Nashan, Peter Schemmer, Felix Braun, Hans J. Schlitt, Andreas Pascher, Christian G. Klein, Ulf P. Neumann, Irena Kroeger, Peter Wimmer, Hephaistos Study Group – 14 September 2021 – Everolimus‐facilitated reduced‐exposure tacrolimus (EVR + rTAC) at 30 days after liver transplantation (LT) has shown advantages in renal preservation. This study evaluated the effects of early initiation of EVR + rTAC in de novo LT recipients (LTRs).